Brokerages expect Gemphire Therapeutics Inc (NASDAQ:GEMP) to report earnings per share (EPS) of ($0.50) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Gemphire Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.41). Gemphire Therapeutics reported earnings of ($0.82) per share in the same quarter last year, which would indicate a positive year over year growth rate of 39%. The company is expected to issue its next quarterly earnings report on Monday, November 12th.
According to Zacks, analysts expect that Gemphire Therapeutics will report full year earnings of ($1.99) per share for the current fiscal year, with EPS estimates ranging from ($2.23) to ($1.86). For the next year, analysts forecast that the business will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.59). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Gemphire Therapeutics.
Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings results on Monday, August 13th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.05.
GEMP has been the topic of several analyst reports. Roth Capital lifted their price target on shares of Gemphire Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price target on shares of Gemphire Therapeutics in a research report on Monday, August 13th. Zacks Investment Research raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Tuesday, August 14th. Jefferies Financial Group lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Monday, August 13th. Finally, ValuEngine upgraded shares of Gemphire Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Gemphire Therapeutics has a consensus rating of “Hold” and an average target price of $17.82.
A number of institutional investors have recently bought and sold shares of GEMP. Millennium Management LLC acquired a new stake in Gemphire Therapeutics in the 2nd quarter valued at approximately $1,981,000. Highland Capital Management LP acquired a new stake in Gemphire Therapeutics in the 1st quarter valued at approximately $700,000. DAFNA Capital Management LLC acquired a new stake in Gemphire Therapeutics in the 1st quarter valued at approximately $651,000. Nomura Holdings Inc. acquired a new stake in Gemphire Therapeutics in the 2nd quarter valued at approximately $556,000. Finally, Acadian Asset Management LLC acquired a new stake in Gemphire Therapeutics in the 2nd quarter valued at approximately $286,000. Hedge funds and other institutional investors own 32.60% of the company’s stock.
Shares of GEMP stock traded down $0.01 during trading on Wednesday, hitting $2.22. 185,000 shares of the stock traded hands, compared to its average volume of 498,092. The firm has a market cap of $32.67 million, a PE ratio of -0.69 and a beta of 1.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.64 and a current ratio of 4.64. Gemphire Therapeutics has a 52-week low of $0.83 and a 52-week high of $11.43.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Recommended Story: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.